Dehydroepiandrosterone and its derivatives: Potentially novel anti-proliferative and chemopreventive agents

Current Pharmaceutical Design

Volumn 12, Issue 26, 2006, Pages 3411-3421

  Matsuzaki, Y ^a   Honda, A ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Ibaraki Prefectural Institute of Public Health   (Japan)

Author keywords

Cancer chemoprevention; Cancer therapy; Dehydroepiandrosterone; Metabolites; Synthetic analogs

Indexed keywords

16ALPHA FLUORO 5ALPHA ANDROSTAN 17 ONE; 3BETA METHYLANDROST 5 EN 17 ONE; ANDROSTERONE; ANTINEOPLASTIC AGENT; CHOLESTEROL; CLOFIBRATE; DEXAMETHASONE; EPIANDROSTERONE; ETIOCHOLANOLONE; FLUASTERONE; FULVESTRANT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOSE 5 PHOSPHATE; STEROID HORMONE; TAMOXIFEN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CANCER; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; THYROID CANCER; TUMOR PROMOTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DEHYDROEPIANDROSTERONE; GROWTH INHIBITORS; HUMANS;

EID: 33748596879     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778194015     Document Type: Review

References (150)

1. Falany CN, Comer KA, Dooley TP, Glatt H. Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization. Ann NY Acad Sci 1995; 774: 59-72.
2. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551-5.
3. Dalla Valle L, Couet J, Labrie Y, Simard J, Belvedere P, Simontacchi C, et al. Occurrence of cytochrome P450c 17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract. Mol Cell Endocrinol 1995; 111: 83-92.
4. 5-derivatives in rat and monkey brain. J Steroid Biochem. 1987; 27: 649-55.
5. Zwain IH, Yen SSC. Dehydroepiandrosterone: biosynthesis and metabolism in the brain. Endocrinology 1999; 140: 880-7.
6. Zwain IH, Yen SSC. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 1999; 140: 3843-52.
7. Svec F, Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 1998; 218: 174-91.
8. Arlt W. Quality life in Addison's disease - the case for DHEA replacement. Clin Endocrinol 2002; 56: 573-4.
9. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003; 361: 1881-93.
10. Johannsson G, Burman P, Wirén L, Engström BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 2046-52.
11. van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2002; 3: 23-31.
12. Petri MA, Lahita RG, van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002; 46: 1820-9.
13. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 2002; 87: 493 5-41.
14. van Broekboven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003; 165: 97-110.
15. Strous RD, Maayan R, Lapidus R, Stryier R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60: 133-41.
16. Giagulli VA, Giorgino R, Vermeulen A. Origin and significance of plasma androsterone glucuronide levels: a parameter of adrenal androgen secretion and hepatic 5α-reductase activity. J Clin Endocrinol Metab 1993; 76: 918-23.
17. Sch⊣nzer W. Metabolism of anabolic androgenic steroids. Clin Chem 1996; 42: 1001-20.
18. Starka L, Kutova J. 7-Hydroxylation of dehydroepiandrosterone by rat-liver homogenate. Biochim Biophys Acta 1962; 56: 76-82.
19. Doostzadeh J, Morfin R. Studies of Me enzyme complex responsible for pregnenolone and dehydroepiandrosterone 7α-hydroxylation in mouse tissues. Steroids 1996; 61: 613-20.
20. Doostzadeh J, Cotillon A-C, Benalycherif A, Morfin R. Inhibition studies of dehydroepiandrosterone 7α- and 7β-hydroxylation in mouse liver microsomes. Steroids 1998; 63: 608-14.
21. Akwa Y, Morfin RF, Robel P, Baulieu EE. Neurosteroid metabolism. 7α-Hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes. Biochem 11992; 288: 959-64.
22. Doostzadeh J, Cotillon AC, Morfin R. Dehydroepiandrosterone 7α- and 7β-hydroxylation in mouse brain microsomes. Effects of cytochrome P450 inhibitors and structure-specific inhibition by steroid hormones. J Neuroendocrinol 1997; 9: 923-8.
23. 14C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue. J Invest Dermatol 1969; 52: 357-61.
24. Lafaye P, Chmielewski V, Nato F, Mazie J-C, Morfin R. The 7α-hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens. Biochim Biophys Acta 1999; 1472: 222-31.
25. 5-3 β-hydroxysteroids in the term human amnion. Endocrinol Exp 1982; 16: 9-17.
26. Li K, Foo T, Adams JB. Products of dehydroepiandrosterone metabolism by human mammary tumors and their influence on estradiol receptor binding. Steroids 1978; 31: 113-27.
27. Fitzpatrick JL, Ripp SL, Smith NB, Pierce WM Jr, Prough RA. Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. Arch Biochem Biophys 2001; 389: 278-87.
28. Marwah A, Marwah P, Lardy H. Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J Chromatogr 2002; 767: 285-99.
29. Rose KA, Stapleton G, Dott K, Kieny MP, Best R, Schwarz M, et al. Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone. Proc Natl Acad Sci USA. 1997; 94: 4925-30.
30. Rose K, Allan A, Gauldie S, Stapleton G, Dobbie L, Doff K, et al. Neurosteroid hydroxylase CYP7B: vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation. J Biol Chem 2001; 276: 23937-44.
31. Yau JL, Rasmuson S, Andrew R, Graham M, Noble J, Olsson T, et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 2003; 121: 307-14.
32. Martin C, Bean R, Rose K, Habib F, Seckl J. Cyp7b1 catalyses the 7α-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem J 2001; 355: 509-15.
33. Wu Z, Martin KO, Javitt NB, Chiang JY. Structure and functions of human oxysterol 7α-hydroxylase cDNAs and gene CYP7B1. J Lipid Res 1999; 40: 2195-203.
34. Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the oxysterol 7α-hydroxylase gene in mice. J Biol Chem 2000; 275: 16536-42.
35. Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102: 1690-703.
36. Lardy H, Partridge B, Kneer N, Wei Y. Ergosteroids: induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone. Proc Natl Acad Sci USA 1995; 92: 6617-9.
37. Lardy H, Kneer N, Wei Y, Partridge B, Marwah P. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998; 63: 158-65.
38. Shi J, Schulze S, Lardy HA. The effect 7-oxo-DHEA acetate on memory in young and old C57BL/6 mice. Steroids 2000; 65: 124-9.
39. Morfin R, Courchay G. Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice. J Steroid Biochem Mol Biol 1994; 50: 91-100.
40. Sterzl I, Hampl R, Sterzl J, Votruba J, Starka L. 7β-OH-DHEA counteracts dexamethasone induced suppression of primary immune response in murine spleenocytes. J Steroid Biochem Mol Biol 1999; 71: 133-7.
41. Padgett DA, Loria RM. Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol. J Neuroimmunol 1998; 84: 61-8.
42. Loria RM, Padgett DA. Control of the immune response, DHEA and its metabolites. Rinsho Byori 1998; 46: 505-17.
43. Pringle AK, Schmidt W, Deans JK, Wulfert E, Reymann KG, Sundstrom LE. 7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro. Eur J Neurosci 2003; 18: 117-24.
44. Coleman DL, Leiter EH, Applezweig N. Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/KsJ-db/ db). Endocrinology 1984; 115: 239-43.
45. Wilpart M, Speder A, Ninane P, Roberfroid M. Antimutagenic effects of natural and synthetic hormonal steroids. Teratog Carcinog Mutagen 1986; 6: 265-73.
46. Yang S, Fu Z, Wang F, Cao Y, Han R. Anti-mutagenicity activity of dehydroepiandrosterone (in Chinese). Zhonghua Zhong Liu Za Zhi 2002; 24: 137-40.
47. Schulz S, Klann RC, Schonfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adeno-carcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res 1992; 52: 1372-6.
48. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, et al. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids 2003; 68: 73-83.
49. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981; 41: 3360-3.
50. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992; 52: 1-4.
51. Heinonen PK, Koivula T, Pystynen P. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. Gynecol Obstet Invest 1987; 23: 271-4.
52. Gordon GB, Helzlsouer KJ, Comstock GW. Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 1991; 51: 1366-9.
53. Gordon GB, Helzlsouer KJ, Alberg AJ, Comstock GW. Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 33-5.
54. Comstock GW, Gordon GB, Hsing AW. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 1993; 2: 219-21.
55. Alberg AJ, Gordon GB, Hoffman SC, Comstock GW, Helzlsouer KJ. Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 517-21.
56. Jones DL, James VH. Determination of dehydroepiandrosterone and dehydroepiandrosterone sulphate in blood and tissue. Studies of normal women and women with breast or endometrial cancer. J Steroid Biochem 1987; 26: 151-9.
57. Yu H, Shu XO, Shi R, Dai Q, Jin F, Gao YT, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer 2003; 105: 92-7.
58. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 274: 1926-30.
59. Alberg AJ, Gordon GB, Genkinger JM, Hoffman SC, Selvin E, Comstock GW, et al. Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and risk of melanoma or squamous cell carcinoma of the skin. Anticancer Res 2001; 21: 4051-4.
60. Skinner SJM, Tobler CJP, Couch RAF. A radioimmunoassay for 7α-hydroxy dehydroepiandrosterone in human plasma. Steroids 1977; 30: 315-30.
61. Trosko JE. Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog 2001; 30: 131137.
62. Moore MA, Thamavit W, Tsuda H, Sato K, Ichihara A, Ito N. Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis 1986; 7: 311-6.
63. Moore MA, Thamavit W, Ichihara A, Sato K, Ito N. Influence of dehydroepiandrosterone, diaminopropane and butylated hydroxyanisole treatment during the induction phase of rat liver nodular lesions in a short-term system. Carcinogenesis 1986; 7: 1059-63.
64. Garcea R, Daino L, Pascale R, Frassetto S, Cozzolino P, Ruggiu ME, et al. Inhibition by dehydroepiandrosterone of liver preneoplastic foci formation in rats after initiation-selection in experimental carcinogenesis. Toxicol Pathol 1987; 15: 164-9.
65. Weber E, Moore MA, Bannasch P. Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomorpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepiandrosterone. Carcinogenesis 1988; 9: 1191-5.
66. Thornton M, Moore MA, Ito N. Modifying influence of dehydroepiandrosterone or butylated hydroxytoluene treatment on initiation and development stages of azaserine-induced acinar pancreatic preneoplastic lesions in the rat. Carcinogenesis 1989; 10: 407-10.
67. Simile M, Pascale RM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, et al. Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer 1995; 62: 210-5.
68. Nyce JW, Magee PN, Hard GC, Schwartz AG. Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone, Carcinogenesis 1984; 5: 57-62.
69. Osawa E, Nakajima A, Yoshida S, Omura M, Nagase H, Ueno N, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci 2002; 70: 2623-30.
70. Schwartz AG, Tannen RH. Inhibition of 7, 12-dimethylbenz[a] anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydrotoepiandrosterone. Carcinogenesis 1981; 2: 1335-7.
71. Pashko LL, Rovito RJ, Williams JR, Sobel EL, Schwartz AG. Dehydroepiandrosterone (DHEA) and 3β-methylandrost-5-en-17-one: inhibitors of 7, 12-dimediylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice. Carcinogenesis 1984; 5: 463-6.
72. Pashko-LL, Hard GC, Rovito RJ, Williams JR, Sobel EL, Schwartz AG. Inhibition of 7, 12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-β-methylandrost-5-en-17-one in mice. Cancer Res 1985; 45: 164-6.
73. Schwartz AG, Fairman DK, Polansky M, Lewbart ML, Pashko LL. Inhibition of 7, 12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs. Carcinogenesis 1989; 10: 1809-13.
74. Ratko TA, Detrisac CJ, Mehta RG, Kelloff GJ, Moon RC. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res 1991; 51: 481-6.
75. McCormick DL, Rao KV, Johnson WD, Bowman-Gram TA, Steele VE, Lubet RA, et al. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res 1996; 56: 1724-6.
76. Lubet RA, Gordon GB, Prough RA, Lei XD, You M, Wang Y, et al. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 1998; 58: 921-6.
77. Shibata MA, Shirai T, Asakawa E, Hirose M, Fukushima S. Inhibition by dehydroepiandrosterone of butylated hydroxyanisole (BHA) promotion of rat-bladder carcinogenesis and enhancement of BHA-induced forestomach hyperplasia. Int J Cancer 1993; 53: 819-23.
78. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999; 59: 3084-9.
79. vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979; 39: 1129-32.
80. Rao MS, Subbarao V, Yeldandi AV, Reddy JK. Inhibition of spontaneous testicular Leydig cell tumor development in F-344 rats by dehydroepiandrosterone. Cancer Lett 1992; 65: 123-6.
81. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigeresis in p53-knockout mice. Cancer Res 1995; 55: 3949-53.
82. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, et al. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/ SV40 T/t-antigen transgenic mice. Cancer Res 2001; 61: 7449-55.
83. Melvin WS, Boros LG, Muscarella P, Brandes JL, Johnson JA, Fisher WE, et al. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery 1997; 121: 392-7.
84. Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psychoneuro-immunological treatment of hepatocellular carcinoma with major depression - a single case report. Curr Med Res Opin 2003; 19: 59-63.
85. Rao MS, Subbarao V, Kumar S, Yeldandi AV, Reddy JK. Phenotypic, properties of liver tumors induced by dehydroepiandrosterone in F-344 rats. Jpn J Cancer Res 1992; 83: 1179-83.
86. Rao MS, Subbarao V, Yeldandi AV, Reddy JK. Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res 1992; 52: 2977-9.
87. Hayashi F, Tamura H, Yamada J, Kasai H, Suga T. Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats. Carcinogenesis 1994; 15: 2215-9.
88. Shibata M, Hasegawa R, Imaida K, Hagiwara A, Ogawa K, Hirose M, et al. Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Cancer Res 1995; 55: 4870-4.
89. Metzger C, Mayer D, Hoffmann H, Bocker T, Hobe G, Benner A, et al. Sequential appearance and ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and female rats treated with dehydroepiandrosterone. Toxicol Pathol 1995; 23: 591-605.
90. Metzger C, Bannasch P, Mayer D. Enhancement and phenotypic modulation of N-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. Cancer Lett 1997; 121: 125-31.
91. Frenkel RA, Slaughter CA, Orth K, Moormaw CR, Hicks SH, Snyder JM, et al. Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding J Steroid Biochem 1990; 35: 333-42.
92. Yamada J, Sakuma M, Ikeda T, Fukuda K, Suga T. Characteristics of dehydroepiandrosterone as a peroxisome proliferator. Biochim Biophys Acta 1991; 1092: 233-43.
93. Rao MS, Musunuri S, Reddy JK. Dehydroepiandrosterone-induced peroxisome proliferation in the rat liver. Pathobiology 1992; 60: 82-6.
94. Sakuma M, Yamada J, Suga T. Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisorne proliferation-associated enzymes in several rodent species. A short-term administration study. Biochem Pharmacol 1992; 43: 1269-73.
95. Sakuma M, Yamada J, Suga T. Induction of peroxisomal β-oxidation by structural analogues of dehydroepiandrosterone in cultured rat hepatocytes: structure-activity relationships. Biochim Biophys Acta 1993; 1169: 66-72.
96. Reddy JK, Rao MS. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res 1989; 214: 63-8.
97. Reddy JK, Qureshi SA. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br J Cancer 1979; 40: 476-82.
98. Tanaka K, Smith PF, Stromberg PC, Eydellot RS, Herold EG, Grossman SJ, et al. Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol 1992; 116: 71-7.
99. Blaauboer BJ, van Holsteijn CW, Bleumink R, Mennes WC, van Pelt FN, Yap SH, et al. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochem Pharmacol 1990; 40: 521-8.
100. Celec P, Starka L. Dehydroepiandrosterone - is the fountain of youth drying out? Physiol Res 2003; 52: 397-407.
101. Calhoun K, Pommier R, Check J, Fletcher W, Toth-Fejel S. The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. Am J Surg 2003; 185: 411-5.
102. Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg 2003; 138: 879-83.
103. Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 2003; 3: 635-41.
104. Marks PA, Banks J. Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids. Proc Natl Acad Sci USA 1960; 46: 447-52.
105. Gordon G, Mackow MC, Levy HR. On the mechanism of interaction of steroids with human glucose 6-phospbate dehydrogenase. Arch Biochem Biophys 1995; 318: 25-9.
106. Tian WN, Braunstein LD, Pang J, Stuhlmier KM, Xi QC, Tian X, et al. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 1998; 273: 10609-17.
107. Sulis E. G.-6-P.D. deficiency and cancer. Lancet 1972; i: 1185.
108. Thakker DR, Yagi H, Lu AY, Levin W, Conney AH. Metabolism of benzo[a]pyrene: conversion of (+/-)-trans-7, 8-dihydroxy-7, 8-dihydrobenzo[a]pyrene to highly mutagenic 7, 8-diol-9, 10-epoxides. Proc Natl Acad Sci USA 1976; 73: 3381-5.
109. Meehan T, Straub K, Calvin M. Benzo[a]pyrene diol epoxide covalently binds to deoxyguanosine and deoxyadenosine in DNA. Nature 1977; 269: 725-7.
110. Feo F, Pirisi L, Pascale R, Daino L, Frassetto S, Zanetti S, et al. Modulatory mechanisms of chemical carcinogenesis: the role of the NADPH pool in the benzo(a)pyrene activation. Toxicol Pathol 1984; 12: 261-8.
111. Garcea R, Daino L, Frassetto S, Cozzolino P, Ruggiu ME, Vannini MG, et al. Reversal by ribo- and deoxyribonucleosides of dehydroepiandrosterone-induced inhibition of enzyme altered foci in the liver of rats subjected to the initiation-selection process of experimental carcinogenesis. Carcinogenesis 1988; 9: 931-8.
112. Feo F, Daino L, Seddaiu MA, Simile MM, Pascale R, McKeating JA, et al. Differential effects of dehydroepiandrosterone and deoxyribonucleosides on DNA synthesis and de novo cholesterogenesis in hepatocarcinogenesis in rats. Carcinogenesis 1991; 12: 1581-6.
113. Biaglow JE, Ayene IS, Koch CJ, Donahue J, Stamato TD, Tuttle SW. G6PD deficient cells and the bioreduction of disulfides: effects of DHEA, GSH depletion and phenylarsine oxide. Biochem Biophys Res Commun 2000; 273: 846-52.
114. Brown MS, Goldstein JL. Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol. J Biol Chem 1974; 249: 7306-14.
115. Pascale RM, Simile MM, De Miglio MR, Nufris A, Seddaiu MA, Muroni MR, et al. Inhibition of 3-hydroxy-3-medtylglutaryl-CoA reductase activity and gene expression by dehydroepiandrosterone in preneoplastic liver nodules. Carcinogenesis 1995; 16: 1537-42.
116. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984; 310: 583-6.
117. Gibbs JB. Ras C-terminal processing enzymes-new drug targets? Cell 1991; 65: 1-4.
118. Krontiris TG. Oncogenes.N Engl J Med 1995; 333:303-6.
119. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/ Jun) activity by glucocorticoid hormone. Cell 1990; 62: 1189-204.
120. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57.
121. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther 1998; 285: 876-83.
122. Bernstein LR, Ferris DK, Colburn NH, Sobel ME. A family of mitogen-activated protein kinase-related proteins interacts in vivo with activator protein-1 transcription factor. J Biol Chem 1994; 269: 9401-4.
123. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369: 156-60.
124. Schwartz A , Pashko LL. Role of adrenocortical steroids in mediating cancer-preventive and age-retarding effects of food restriction in laboratory rodents. J Gerontol 1994; 49: B37-B41.
125. Roecker EB, Kemnitz JW, Ershler WB, Weindruch R. Reduced immune responses in rhesus monkeys subjected to dietary restriction. J Gerontol A Biol Sci Med Sci 1996; 51: B276-B9.
126. Wachsman JT. The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Mutat Res 1996; 350: 25-34.
127. Mei JJ, Hursting SD, Perkins SN, Phang JM. p53-independent inhibition of nitric oxide generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages. Cancer Lett 1998; 129: 191-7.
128. Laychock SG, Bauer AL. Epiandrosterone and dehydrodpiandrosterone affect glucose oxidation and interleukin-1β effects in pancreatic islets. Endocrinology 1996; 137: 3375-85.
129. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50 .
130. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994; 305: 253-64.
131. Hursting SD, Perkin; SN, Phang JM. Calorie restriction delays. spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 1994; 91: 7036-40.
132. Yang NC, Jeng KC, Ho WK Hu ML. ATP depletion is an important factor in DHEA-induced growth inhibition and apoptosis in BV-2 cells. Life Sci 2002; 70: 1979-88.
133. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 2002; 67: 953-66.
134. Jiang Y, Miyazaki T, Honda A, Hirayama T, Yoshida S, Tanaka N, et al. Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J Gastroenterol 2005; 40: 490-7.
135. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696-704.
136. Sunde A, Aareskjold K, Haug E, Eik-Nes KB. Synthesis and androgen effects of 7α 17β-dihydroxy-5α-androstan-3-one, 5α-androstan-3α, 7α, 17β-triol and 5α-androstane-3β 7α, 17β-triol. J Steroid Biochem 1982; 16: 483-38.
137. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr Pharm Des 2003; 9: 2067-77.
138. Okabe T, Haji M, Takayanagi R, Adachi M, Imasaki K, Kurimoto F, et al. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995; 80: 2993-6.
139. Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, et al. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992; 42: 293-304.
140. Yamada J, Sugiyama H, Sakuma M, Suga T. Specific binding of dehydroepiandrosterone sulfate to rat liver cytosol: a possible association with peroxisomal enzyme induction. Biochim Biophys Acta 1994; 1224: 139-46.
141. 3H] DHEA binding in rat liver. Biochem Biophys Res Commun 1988; 156: 22-9.
142. Imai A, Ohno T, Tamaya T. Dehydroepiandrosterone sulfate-binding. sites in plasma membrane from human uterine cervical fibroblasts. Experientia 1992; 48: 999-1002.
143. Ripp, SL, Fitzpatrick JL, Peters JM, Prough RA. Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab, Dispos 2002; 30: 570-5.
144. Fujita A, Furutama D, Tanaka T, Sakai R, Koyama A, Hanafusa T, et al. In vivo activation of the constitutive androstane receptor beta (CARβ) by treatment with debydroepiandrosterone (DHEA) or DHEA sulfate (DHEA-S). FEBS Lett 2002; 532: 373-8.
145. Kajita K, Ishizuka T, Mune T, Miura A, Ishizawa M, Kanoh Y, et al. Dehydroepiandrosterone down-regulates the expression of peroxisome proliferator-activated receptor γ in adipocytes. Endocrinology 2003; 144: 253-9.
146. Mastrocola R, Aragno M, Betteto S, Brignardello E, Catalano MG, Danni O, et al. Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci 2003; 73: 189-99.
147. Stoffel-Wagner B. Neurosteroid metabolism human brain. Eur J Endocrinol 2001; 145: 669-79.
148. 12,3. J Biol Chem 2002; 277: 21379-88.
149. Corsini E, Lucchi L, Meroni M, Racchi M, Solerte B, Fioravanti M, et al. In vivo dehydroepiandrosterone restores age-associated defects in the protein kinase C signal transduction pathway and related functional responses. J Immunol 2002; 168: 1753-8.
150. Silvagno F, Guarnieri V, Capizzi A, Pescarmona GP. Sergistic effect of retinoic acid and dehydroepiandrosterone on differentiation of human neuroblastoma cells. FEBS Lett 2002; 532: 153-8.